In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best magic formula stocks to invest in. On July 10, UBS reiterated its Buy ...

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

"These breakthroughs have been lifesaving — for me and so many others who rely on cancer therapy." writes one reader.